Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 3 at the Top Dose of 18 mg/kg in Entrada Therapeutics’ ELEVATE-44-201 Study
Entrada Therapeutics announced that an independent Data Monitoring Committee recommended initiating Cohort 3 of the ELEVATE-44-201 Phase 1/2 study at the top dose of 18 mg/kg, up from 12 mg/kg in Cohort 2. The DMC reviewed safety and PK data from eight participants in the double-blind, placebo-controlled multiple-ascending-dose portion of the study of ENTR-601-44, an exon 44-skipping candidate for Duchenne muscular dystrophy.
Key figures
- Drug Name
- ENTR-601-44
- Phase Of Trial
- Phase 1/2
- Cohort1 dose
- 6 mg/kg
- Cohort2 dose
- 12 mg/kg
- Cohort3 dose
- 18 mg/kg
- Cohort1 data timing
- by year-end 2026
- Cohort2 data timing
- Q1 2027
- Cohort2 participants
- 8
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.